ERYTECH Secures US Patent Directed to Sequential Use of Methioninase & Asparaginase against Solid Tumors Prior treatment with methioninase shown to sensitize certain solid tumor types to asparaginase-based treatment New patent granting adding to portfolio of 310 granted patents in 16 patent
Conference call and webcast on Tuesday, November 16, 2021 at 8:30am EST / 2:30pm CET Progress towards seeking approval of eryaspase for the treatment of ALL patients who experienced hypersensitivity to pegylated asparaginase ; Fast Track designation granted; submission of BLA
ERYTECH Announces Upcoming Poster Presentation at the 2021 American Society of Hematology Annual Meeting Cambridge, MA (U.S.) and Lyon (France) , November 1 5 , 202 1 – ERYTECH Pharma (Nasdaq & Euronext: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by
ERYTECH Announces Publication of a Paper on Red-Blood Cell Characterization in High Impact Peer Reviewed Journal The Paper "Multiparametric characterization of red blood cell physiology after hypotonic dialysis based drug encapsulation process" is available in the October 2021 (Volume 11, Issue 10)
Article 223-16 of general regulation of French Autorité des Marchés Financiers Lyon – France Listing markets: Euronext Paris from Euronext (Market segment C - ISIN Code: FR0011471135- Symbol: ERYP) & Nasdaq Global Select Market in the United-States (Symbol : ERYP) Website : www.erytech.com Date
ERYTECH Announces Results from TRYbeCA-1 Phase 3 Trial of Eryaspase in Patients with Second-line Advanced Pancreatic Cancer Management to host Conference Call on Monday, October 25, at 8:30am EDT/ 2:30pm CEST T he trial did not meet its primary endpoint of overall survival The prespecified
Monthly information related to total number of voting rights and shares composing the share capital – September 3 0 , 2021. Article 223-16 of general regulation of French Autorité des Marchés Financiers Lyon – France Listing markets: Euronext Paris from Euronext (Market segment C -
ERYTECH Announces M aximum Tolerated Dose Declared in a Phase 1 Investigator Sponsored Trial of Eryaspase in First -Line Pancreatic Cancer No d ose - l imiting t oxicity (DLT) reported in first two dose cohorts, leading to de c laration of the m aximum t olerated d ose (MTD) at 100 U/kg Encouraging
ERYTECH to Participate in the HealthTech Innovation Days (HTID) by France Biotech Cambridge, MA (U.S.) and Lyon (France), September 28 , 2021 – ERYTECH Pharma (Nasdaq & Euronext: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug
ERYTECH Announces the A vailability of its H alf- Y ear F inancial R eport 202 1 Lyon (France) a nd Cambridge, MA (U.S.), Septembre 2 2 , 202 1 – ERYTECH Pharma (Nasdaq & Euronext: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug
